Mibefradil (Synonyms: Ro 40-5967)

製品番号: HY-15553: Data Sheet 取扱説明書
FAQs
Technical Support

Mibefradil (Ro 40-5967) is a calcium channel blocker with moderate selectivity for T-type Ca²⁺ channels displaying IC₅₀s of 2.7 μM and 18.6 μM for T-type and L-type currents, respectively.

The free form of the compound is prone to instability, it is advisable to consider the stable salt form (Mibefradil dihydrochloride) that retains the same biological activity.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

Mibefradil 構造式

CAS 番号 : 116644-53-2

容量	価格（税別）	在庫状況
1 mg	$140	見積もりとリードタイムを求めるのご確認
5 mg	$350	見積もりとリードタイムを求めるのご確認
10 mg	$550	見積もりとリードタイムを求めるのご確認
25 mg	$1220	見積もりとリードタイムを求めるのご確認
50 mg	$1980	見積もりとリードタイムを求めるのご確認

* アイテムを追加する前、数量をご選択ください

This product is a controlled substance and not for sale in your territory.

Other 在庫あり Forms of Mibefradil:

Mibefradil dihydrochloride

Other Forms of Mibefradil:

Mibefradil dihydrochloride 在庫あり
Mibefradil dihydrochloride hydrate お問い合わせ

顧客検証

Calcium Channel アイソフォーム固有の製品をすべて表示:

すべてのアイソフォームを表示

N-type calcium channel L-type calcium channel P/Q-type calcium channel T-type calcium channel Calcium Channel

生物活性
プロトコル
純度とドキュメンテーション
参考文献
カスタマーレビュー

製品説明

IC₅₀ & Target

L-type calcium channel

T-type calcium channel

Cellular Effect

Cell Line	Type	Value	Description	References
A2780	IC₅₀	24.23 3 Compound: Mibefradil	Cytotoxicity against human A2780 cells after 48 hrs by MTT assay Cytotoxicity against human A2780 cells after 48 hrs by MTT assay	[PMID: 24220170]
A2780	IC₅₀	24.23 3 Compound: Mibefradil	Cytotoxicity against human A2780 cells after 48 hrs by MTT assay Cytotoxicity against human A2780 cells after 48 hrs by MTT assay	[PMID: 24220170]
A2780	IC₅₀	24.23 3 Compound: Mibefradil	Cytotoxicity against human A2780 cells after 48 hrs by MTT assay Cytotoxicity against human A2780 cells after 48 hrs by MTT assay	[PMID: 24220170]
A2780/Taxol	IC₅₀	35.26 3 Compound: Mibefradil	Cytotoxicity against human paclitaxel-resistant A2780T cells after 48 hrs by MTT assay Cytotoxicity against human paclitaxel-resistant A2780T cells after 48 hrs by MTT assay	[PMID: 24220170]
A2780/Taxol	IC₅₀	35.26 3 Compound: Mibefradil	Cytotoxicity against human paclitaxel-resistant A2780T cells after 48 hrs by MTT assay Cytotoxicity against human paclitaxel-resistant A2780T cells after 48 hrs by MTT assay	[PMID: 24220170]
A2780/Taxol	IC₅₀	35.26 3 Compound: Mibefradil	Cytotoxicity against human paclitaxel-resistant A2780T cells after 48 hrs by MTT assay Cytotoxicity against human paclitaxel-resistant A2780T cells after 48 hrs by MTT assay	[PMID: 24220170]
A549	IC₅₀	24.8 3 Compound: Mibefradil	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	[PMID: 24529871]
A549	IC₅₀	24.8 3 Compound: Mibefradil	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	[PMID: 24529871]
A549	IC₅₀	24.9 3 Compound: Mibefradil	Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 32327350]
A549	IC₅₀	24.9 3 Compound: Mibefradil	Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 32327350]
A549	IC₅₀	31.4 3 Compound: Mibefradil	Cytotoxicity against human A549 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability by MTT assay	[PMID: 26739776]
A549	IC₅₀	31.4 3 Compound: Mibefradil	Cytotoxicity against human A549 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability by MTT assay	[PMID: 26739776]
CHO	IC₅₀	0.51 3 Compound: mibefradil	Inhibition of Cav1.2 current measured using QPatch automatic path clamp system in CHO cells expressing Cav1.2, beta-2 and alpha-2/delta-1 subunits Inhibition of Cav1.2 current measured using QPatch automatic path clamp system in CHO cells expressing Cav1.2, beta-2 and alpha-2/delta-1 subunits	[PMID: 23812503]
Hepatocyte	IC₅₀	0.873 1 Compound: Mibefradil	Antimicrobial activity against Plasmodium yoelii 265 liver infected in mammalian hepatocytes after 48 hrs Antimicrobial activity against Plasmodium yoelii 265 liver infected in mammalian hepatocytes after 48 hrs	[PMID: 18212104]
CHO	IC₅₀	3.3 3 Compound: Mibefradil	Inhibition of human ERG expressed in CHO cells by IONWORKS assay Inhibition of human ERG expressed in CHO cells by IONWORKS assay	[PMID: 23200256]
HEK293	IC₅₀	0.13 3 Compound: 1, Mibefradil	Antagonist activity at human alpha1H T-type calcium channel expressed in HEK293 cells by patch clamp technique Antagonist activity at human alpha1H T-type calcium channel expressed in HEK293 cells by patch clamp technique	[PMID: 18160281]
CHO	IC₅₀	0.51 3 Compound: mibefradil	Inhibition of Cav1.2 current measured using QPatch automatic path clamp system in CHO cells expressing Cav1.2, beta-2 and alpha-2/delta-1 subunits Inhibition of Cav1.2 current measured using QPatch automatic path clamp system in CHO cells expressing Cav1.2, beta-2 and alpha-2/delta-1 subunits	[PMID: 23812503]
HEK293	IC₅₀	0.2 3 Compound: 1	Inhibition of human Cav3.1 alpha1G expressed in HEK293 cells assessed as inhibition of calcium influx by FLIPR assay Inhibition of human Cav3.1 alpha1G expressed in HEK293 cells assessed as inhibition of calcium influx by FLIPR assay	[PMID: 21875808]
HEK293	IC₅₀	0.56 3 Compound: Mibefradil	Inhibition of T-type CaV3.1 channel (unknown origin) expressed in HEK293 cells assessed as inhibition of calcium current by whole cell patch-clamp method Inhibition of T-type CaV3.1 channel (unknown origin) expressed in HEK293 cells assessed as inhibition of calcium current by whole cell patch-clamp method	[PMID: 24529871]
CHO	IC₅₀	3.3 3 Compound: Mibefradil	Inhibition of human ERG expressed in CHO cells by IONWORKS assay Inhibition of human ERG expressed in CHO cells by IONWORKS assay	[PMID: 23200256]
HEK293	IC₅₀	1.34 3 Compound: Mibefradil	Ability to block calcium channel T type 3.1v expressed in HEK293 cells by whole cell patch clamp method Ability to block calcium channel T type 3.1v expressed in HEK293 cells by whole cell patch clamp method	[PMID: 16876404]
HEK293	IC₅₀	0.56 3 Compound: Mibefradil	Inhibition of t-type Cav3.1 channel (unknown origin) expressed in HEK293 cells assessed as inhibition of 50 ms depolarizing voltage step-induced current by whole cell patch-clamp method Inhibition of t-type Cav3.1 channel (unknown origin) expressed in HEK293 cells assessed as inhibition of 50 ms depolarizing voltage step-induced current by whole cell patch-clamp method	[PMID: 24220170]
HEK293	IC₅₀	0.13 3 Compound: 1, Mibefradil	Antagonist activity at human alpha1H T-type calcium channel expressed in HEK293 cells by patch clamp technique Antagonist activity at human alpha1H T-type calcium channel expressed in HEK293 cells by patch clamp technique	[PMID: 18160281]
HEK293	IC₅₀	0.83 3 Compound: Mibefradil	Inhibition of alpha-1G calcium channel in human HEK293 cells by whole-cell patch-clamp method Inhibition of alpha-1G calcium channel in human HEK293 cells by whole-cell patch-clamp method	[PMID: 23395659]
HEK293	IC₅₀	0.83 3 Compound: Mibefradil	Inhibition of T-type CaV3.1 channel expressed in HEK293 cells assessed as inhibition of calcium current by automated patch-clamp assay Inhibition of T-type CaV3.1 channel expressed in HEK293 cells assessed as inhibition of calcium current by automated patch-clamp assay	[PMID: 20621730]
HEK293	IC₅₀	1.34 3 Compound: mibefradil	Antagonist activity at T type calcium channel alpha1G expressed in HEK293 cells assessed as inhibition of peak currents by whole-cell patch-clamp method Antagonist activity at T type calcium channel alpha1G expressed in HEK293 cells assessed as inhibition of peak currents by whole-cell patch-clamp method	[PMID: 18625556]
HEK293	IC₅₀	0.84 3 Compound: mibefradil	Inhibition of alpha-1G T-type calcium channel expressed in HEK293 cells by electrophysiological method Inhibition of alpha-1G T-type calcium channel expressed in HEK293 cells by electrophysiological method	[PMID: 17074493]
HEK293	IC₅₀	0.84 3 Compound: Midefradil	Concentration of the compounds required for inhibition of HEK293 cells (alpha1G T-type) Concentration of the compounds required for inhibition of HEK293 cells (alpha1G T-type)	[PMID: 15177437]
HEK293	IC₅₀	0.86 3 Compound: Mibefradil	Inhibition of T-type CaV3.1 channel expressed in HEK293 cells assessed as inhibition of calcium current by manual patch-clamp assay Inhibition of T-type CaV3.1 channel expressed in HEK293 cells assessed as inhibition of calcium current by manual patch-clamp assay	[PMID: 20621730]
HEK293	IC₅₀	0.83 3 Compound: Mibefradil	Inhibition of alpha-1G calcium channel in human HEK293 cells by whole-cell patch-clamp method Inhibition of alpha-1G calcium channel in human HEK293 cells by whole-cell patch-clamp method	[PMID: 23395659]
HEK293	IC₅₀	0.84 3 Compound: mibefradil	Inhibition of alpha-1G T-type calcium channel expressed in HEK293 cells by electrophysiological method Inhibition of alpha-1G T-type calcium channel expressed in HEK293 cells by electrophysiological method	[PMID: 17074493]
HEK293	IC₅₀	1 3 Compound: Mibefradil	Inhibition of human T-type calcium channel Cav3.2 expressed in T-Rex293 cells by whole cell patch clamp assay Inhibition of human T-type calcium channel Cav3.2 expressed in T-Rex293 cells by whole cell patch clamp assay	[PMID: 23200256]
HEK293	IC₅₀	1.3 3 Compound: I, Posicor	Inhibition of human ERG expressed in HEK cells by patch clamp assay Inhibition of human ERG expressed in HEK cells by patch clamp assay	[PMID: 26231163]
HEK293	IC₅₀	0.2 3 Compound: 1	Inhibition of human Cav3.1 alpha1G expressed in HEK293 cells assessed as inhibition of calcium influx by FLIPR assay Inhibition of human Cav3.1 alpha1G expressed in HEK293 cells assessed as inhibition of calcium influx by FLIPR assay	[PMID: 21875808]
HEK293	IC₅₀	1.3 3 Compound: I, Posicor	Inhibition of human ERG expressed in HEK cells by patch clamp assay Inhibition of human ERG expressed in HEK cells by patch clamp assay	[PMID: 26231163]
HEK293	IC₅₀	1.34 3 Compound: Mibefradil	Inhibition of T-type alpha1G channel expressed in HEK293 cells by whole-cell patch-clamp method Inhibition of T-type alpha1G channel expressed in HEK293 cells by whole-cell patch-clamp method	[PMID: 20659804]
HEK293	IC₅₀	1.34 3 Compound: Mibefradil	Inhibition of T-type calcium channel alpha1G expressed in human HEK293 cells assessed as inhibition of peak currents by whole-cell patch-clamp method Inhibition of T-type calcium channel alpha1G expressed in human HEK293 cells assessed as inhibition of peak currents by whole-cell patch-clamp method	[PMID: 20382529]
HEK293	IC₅₀	1 3 Compound: Mibefradil	Inhibition of human T-type calcium channel Cav3.2 expressed in T-Rex293 cells by whole cell patch clamp assay Inhibition of human T-type calcium channel Cav3.2 expressed in T-Rex293 cells by whole cell patch clamp assay	[PMID: 23200256]
A549	IC₅₀	24.8 3 Compound: Mibefradil	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	[PMID: 24529871]
HEK293	IC₅₀	1.34 3 Compound: mibefradil	Antagonist activity at T type calcium channel alpha1G expressed in HEK293 cells assessed as inhibition of peak currents by whole-cell patch-clamp method Antagonist activity at T type calcium channel alpha1G expressed in HEK293 cells assessed as inhibition of peak currents by whole-cell patch-clamp method	[PMID: 18625556]
A549	IC₅₀	24.9 3 Compound: Mibefradil	Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 32327350]
HEK293	IC₅₀	1.34 3 Compound: Mibefradil	Inhibition of T type calcium channel subunit alpha-1G expressed in HEK293 cells assessed as effect on T-type calcium currents by patch clamp method Inhibition of T type calcium channel subunit alpha-1G expressed in HEK293 cells assessed as effect on T-type calcium currents by patch clamp method	[PMID: 17150365]
HEK293	IC₅₀	1.34 3 Compound: mibefradil	Inhibition of T-type calcium channel Cav3.1 alpha-1G subunit expressed in HEK293 cells assessed as calcium current by patch-clamp assay Inhibition of T-type calcium channel Cav3.1 alpha-1G subunit expressed in HEK293 cells assessed as calcium current by patch-clamp assay	[PMID: 17869104]
HEK293	IC₅₀	1.34 3 Compound: Mibefradil	Inhibition of T-type [Ca2+] channel (alpha1G) expressed in HEK293 cells Inhibition of T-type [Ca2+] channel (alpha1G) expressed in HEK293 cells	[PMID: 15603940]
A549	IC₅₀	31.4 3 Compound: Mibefradil	Cytotoxicity against human A549 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability by MTT assay	[PMID: 26739776]
HEK293	IC₅₀	1.34 3 Compound: Mibefradil	Inhibition of T-type alpha1G calcium channel expressed in HEK293 cells assessed as Kcl-induced depolarization Inhibition of T-type alpha1G calcium channel expressed in HEK293 cells assessed as Kcl-induced depolarization	[PMID: 21126876]
HEK293	IC₅₀	1.34 3 Compound: Mibefradil	Inhibition of T type calcium channel subunit alpha-1G expressed in HEK293 cells assessed as effect on T-type calcium currents by patch clamp method Inhibition of T type calcium channel subunit alpha-1G expressed in HEK293 cells assessed as effect on T-type calcium currents by patch clamp method	[PMID: 17150365]
CHO	IC₅₀	0.51 3 Compound: mibefradil	Inhibition of Cav1.2 current measured using QPatch automatic path clamp system in CHO cells expressing Cav1.2, beta-2 and alpha-2/delta-1 subunits Inhibition of Cav1.2 current measured using QPatch automatic path clamp system in CHO cells expressing Cav1.2, beta-2 and alpha-2/delta-1 subunits	[PMID: 23812503]
HEK293	IC₅₀	1.34 3 Compound: Mibefradil	Inhibition of T-type alpha1G channel expressed in HEK293 cells by whole-cell patch-clamp method Inhibition of T-type alpha1G channel expressed in HEK293 cells by whole-cell patch-clamp method	[PMID: 20659804]
CHO	IC₅₀	3.3 3 Compound: Mibefradil	Inhibition of human ERG expressed in CHO cells by IONWORKS assay Inhibition of human ERG expressed in CHO cells by IONWORKS assay	[PMID: 23200256]
HEK293	IC₅₀	1.34 3 Compound: mibefradil	Inhibition of T-type calcium channel Cav3.1 expressed in HEK293 cells co-expressing alpha1G subunit and Kir2.1 potassium channel by patch-clamp assay Inhibition of T-type calcium channel Cav3.1 expressed in HEK293 cells co-expressing alpha1G subunit and Kir2.1 potassium channel by patch-clamp assay	[PMID: 17092715]
HEK293	IC₅₀	1.34 3 Compound: mibefradil	Inhibition of T-type calcium channel Cav3.1 expressed in HEK293 cells co-expressing alpha1G subunit by whole-cell patch clamp method Inhibition of T-type calcium channel Cav3.1 expressed in HEK293 cells co-expressing alpha1G subunit by whole-cell patch clamp method	[PMID: 17064894]
COS-7	IC₅₀	1430 1 Compound: 18 (Mibefradil)	K+ channel blocking activity in COS-7 African green monkey kidney derived cells expressing HERG Kv11.1 K+ channel blocking activity in COS-7 African green monkey kidney derived cells expressing HERG Kv11.1	[PMID: 12190308]
HEK293	IC₅₀	1.34 3 Compound: Mibefradil	Inhibition of T-type calcium channel alpha1G expressed in human HEK293 cells assessed as inhibition of peak currents by whole-cell patch-clamp method Inhibition of T-type calcium channel alpha1G expressed in human HEK293 cells assessed as inhibition of peak currents by whole-cell patch-clamp method	[PMID: 20382529]
HEK293	IC₅₀	1.34 3 Compound: mibefradil	Inhibition of T-type calcium channel Cav3.1 alpha-1G subunit expressed in HEK293 cells assessed as calcium current by patch-clamp assay Inhibition of T-type calcium channel Cav3.1 alpha-1G subunit expressed in HEK293 cells assessed as calcium current by patch-clamp assay	[PMID: 17869104]
HEK293	IC₅₀	1.34 3 Compound: Mibefradil	Ability to block calcium channel T type 3.1v expressed in HEK293 cells by whole cell patch clamp method Ability to block calcium channel T type 3.1v expressed in HEK293 cells by whole cell patch clamp method	[PMID: 16876404]
HEK293	IC₅₀	181 1 Compound: I, Posicor	Inhibition of recombinant Cav3.2 channel (unknown origin) expressed in HEK293 cells assessed as effect on calcium flux incubated for 3 mins by FLIPR assay Inhibition of recombinant Cav3.2 channel (unknown origin) expressed in HEK293 cells assessed as effect on calcium flux incubated for 3 mins by FLIPR assay	[PMID: 26231163]
Caco-2	IC₅₀	1.2 3 Compound: Mibefradil	TP_TRANSPORTER: inhibition of Digoxin transepithelial transport (basal to apical) (Digoxin: 5 uM) in Caco-2 cells TP_TRANSPORTER: inhibition of Digoxin transepithelial transport (basal to apical) (Digoxin: 5 uM) in Caco-2 cells	[PMID: 11961113]
HEK293	IC₅₀	1.34 3 Compound: mibefradil	Inhibition of T-type calcium channel Cav3.1 expressed in HEK293 cells co-expressing alpha1G subunit and Kir2.1 potassium channel by patch-clamp assay Inhibition of T-type calcium channel Cav3.1 expressed in HEK293 cells co-expressing alpha1G subunit and Kir2.1 potassium channel by patch-clamp assay	[PMID: 17092715]
HEK293	IC₅₀	1.34 3 Compound: mibefradil	Inhibition of T-type calcium channel Cav3.1 expressed in HEK293 cells co-expressing alpha1G subunit by whole-cell patch clamp method Inhibition of T-type calcium channel Cav3.1 expressed in HEK293 cells co-expressing alpha1G subunit by whole-cell patch clamp method	[PMID: 17064894]
HEK293	IC₅₀	202 1 Compound: I, Posicor	Inhibition of recombinant Cav1.2 channel (unknown origin) expressed in HEK293 cells assessed as effect on calcium flux incubated for 3 mins by FLIPR assay Inhibition of recombinant Cav1.2 channel (unknown origin) expressed in HEK293 cells assessed as effect on calcium flux incubated for 3 mins by FLIPR assay	[PMID: 26231163]
Caco-2	IC₅₀	1.6 3 Compound: Mibefradil	TP_TRANSPORTER: inhibition of Digoxin transepithelial transport (basal to apical) (Digoxin: 5 uM) in Caco-2 cells TP_TRANSPORTER: inhibition of Digoxin transepithelial transport (basal to apical) (Digoxin: 5 uM) in Caco-2 cells	[PMID: 10901697]
HEK293	IC₅₀	0.56 3 Compound: Mibefradil	Inhibition of t-type Cav3.1 channel (unknown origin) expressed in HEK293 cells assessed as inhibition of 50 ms depolarizing voltage step-induced current by whole cell patch-clamp method Inhibition of t-type Cav3.1 channel (unknown origin) expressed in HEK293 cells assessed as inhibition of 50 ms depolarizing voltage step-induced current by whole cell patch-clamp method	[PMID: 24220170]
HeLa	IC₅₀	4.32 3 Compound: Mibefradil	Inhibition of Ebolavirus glycoprotein/matrix protein VP40 entry in human HeLa cells after 4.5 hrs beta-lactamase reporter assay Inhibition of Ebolavirus glycoprotein/matrix protein VP40 entry in human HeLa cells after 4.5 hrs beta-lactamase reporter assay	[PMID: 29624387]
HEK293	IC₅₀	0.56 3 Compound: Mibefradil	Inhibition of T-type CaV3.1 channel (unknown origin) expressed in HEK293 cells assessed as inhibition of calcium current by whole cell patch-clamp method Inhibition of T-type CaV3.1 channel (unknown origin) expressed in HEK293 cells assessed as inhibition of calcium current by whole cell patch-clamp method	[PMID: 24529871]
Hepatocyte	IC₅₀	0.873 1 Compound: Mibefradil	Antimicrobial activity against Plasmodium yoelii 265 liver infected in mammalian hepatocytes after 48 hrs Antimicrobial activity against Plasmodium yoelii 265 liver infected in mammalian hepatocytes after 48 hrs	[PMID: 18212104]
HEK293	IC₅₀	0.83 3 Compound: Mibefradil	Inhibition of T-type CaV3.1 channel expressed in HEK293 cells assessed as inhibition of calcium current by automated patch-clamp assay Inhibition of T-type CaV3.1 channel expressed in HEK293 cells assessed as inhibition of calcium current by automated patch-clamp assay	[PMID: 20621730]
LLC-PK1	IC₅₀	1.8 3 Compound: Mibefradil	Inhibition of P-glycoprotein, human L-MDR1 expressed in LLC-PK1 epithelial cells using calcein-AM polarisation assay Inhibition of P-glycoprotein, human L-MDR1 expressed in LLC-PK1 epithelial cells using calcein-AM polarisation assay	[PMID: 12699389]
HEK293	IC₅₀	0.13 3 Compound: 1, Mibefradil	Antagonist activity at human alpha1H T-type calcium channel expressed in HEK293 cells by patch clamp technique Antagonist activity at human alpha1H T-type calcium channel expressed in HEK293 cells by patch clamp technique	[PMID: 18160281]
HEK293	IC₅₀	0.86 3 Compound: Mibefradil	Inhibition of T-type CaV3.1 channel expressed in HEK293 cells assessed as inhibition of calcium current by manual patch-clamp assay Inhibition of T-type CaV3.1 channel expressed in HEK293 cells assessed as inhibition of calcium current by manual patch-clamp assay	[PMID: 20621730]
LLC-PK1	IC₅₀	10 3 Compound: Mibefradil	Inhibition of P-glycoprotein, mouse L-mdr1b expressed in LLC-PK1 epithelial cells using calcein-AM polarisation assay Inhibition of P-glycoprotein, mouse L-mdr1b expressed in LLC-PK1 epithelial cells using calcein-AM polarisation assay	[PMID: 12699389]
HEK293	IC₅₀	0.2 3 Compound: 1	Inhibition of human Cav3.1 alpha1G expressed in HEK293 cells assessed as inhibition of calcium influx by FLIPR assay Inhibition of human Cav3.1 alpha1G expressed in HEK293 cells assessed as inhibition of calcium influx by FLIPR assay	[PMID: 21875808]
HeLa	IC₅₀	4.32 3 Compound: Mibefradil	Inhibition of Ebolavirus glycoprotein/matrix protein VP40 entry in human HeLa cells after 4.5 hrs beta-lactamase reporter assay Inhibition of Ebolavirus glycoprotein/matrix protein VP40 entry in human HeLa cells after 4.5 hrs beta-lactamase reporter assay	[PMID: 29624387]
LLC-PK1	IC₅₀	7.4 3 Compound: Mibefradil	Inhibition of P-glycoprotein, mouse L-mdr1a expressed in LLC-PK1 epithelial cells using calcein-AM polarisation assay Inhibition of P-glycoprotein, mouse L-mdr1a expressed in LLC-PK1 epithelial cells using calcein-AM polarisation assay	[PMID: 12699389]
HEK293	IC₅₀	0.56 3 Compound: Mibefradil	Inhibition of t-type Cav3.1 channel (unknown origin) expressed in HEK293 cells assessed as inhibition of 50 ms depolarizing voltage step-induced current by whole cell patch-clamp method Inhibition of t-type Cav3.1 channel (unknown origin) expressed in HEK293 cells assessed as inhibition of 50 ms depolarizing voltage step-induced current by whole cell patch-clamp method	[PMID: 24220170]
MDA-MB-231	IC₅₀	> 100 3 Compound: 8	Inhibition of Orai1-mediated store operated Ca2+ entry in human MDA-MB-231 cells assessed as reduction in BAPTA-induced Ca2+ depletion-stimulated SOCE activity preincubated for 15 mins followed by BAPTA addition in presence of extracellular Ca2+ by PBX-ba Inhibition of Orai1-mediated store operated Ca2+ entry in human MDA-MB-231 cells assessed as reduction in BAPTA-induced Ca2+ depletion-stimulated SOCE activity preincubated for 15 mins followed by BAPTA addition in presence of extracellular Ca2+ by PBX-ba	[PMID: 27856238]
LLC-PK1	IC₅₀	1.8 3 Compound: Mibefradil	Inhibition of P-glycoprotein, human L-MDR1 expressed in LLC-PK1 epithelial cells using calcein-AM polarisation assay Inhibition of P-glycoprotein, human L-MDR1 expressed in LLC-PK1 epithelial cells using calcein-AM polarisation assay	[PMID: 12699389]
HEK293	IC₅₀	0.56 3 Compound: Mibefradil	Inhibition of T-type CaV3.1 channel (unknown origin) expressed in HEK293 cells assessed as inhibition of calcium current by whole cell patch-clamp method Inhibition of T-type CaV3.1 channel (unknown origin) expressed in HEK293 cells assessed as inhibition of calcium current by whole cell patch-clamp method	[PMID: 24529871]
MDA-MB-231	IC₅₀	52.1 3 Compound: 8	Inhibition of Orai1-mediated store operated Ca2+ entry in human MDA-MB-231 cells assessed as reduction of SERCA inhibition-induced ER release preincubated for 15 mins followed by CPA addition by PBX-based FLIPR assay Inhibition of Orai1-mediated store operated Ca2+ entry in human MDA-MB-231 cells assessed as reduction of SERCA inhibition-induced ER release preincubated for 15 mins followed by CPA addition by PBX-based FLIPR assay	[PMID: 27856238]
HEK293	IC₅₀	0.83 3 Compound: Mibefradil	Inhibition of T-type CaV3.1 channel expressed in HEK293 cells assessed as inhibition of calcium current by automated patch-clamp assay Inhibition of T-type CaV3.1 channel expressed in HEK293 cells assessed as inhibition of calcium current by automated patch-clamp assay	[PMID: 20621730]
LLC-PK1	IC₅₀	7.4 3 Compound: Mibefradil	Inhibition of P-glycoprotein, mouse L-mdr1a expressed in LLC-PK1 epithelial cells using calcein-AM polarisation assay Inhibition of P-glycoprotein, mouse L-mdr1a expressed in LLC-PK1 epithelial cells using calcein-AM polarisation assay	[PMID: 12699389]
MIA PaCa-2	IC₅₀	18.4 3 Compound: Mibefradil	Cytotoxicity against human MIAPaCa2 cells after 48 hrs by MTT assay Cytotoxicity against human MIAPaCa2 cells after 48 hrs by MTT assay	[PMID: 24529871]
HEK293	IC₅₀	0.83 3 Compound: Mibefradil	Inhibition of alpha-1G calcium channel in human HEK293 cells by whole-cell patch-clamp method Inhibition of alpha-1G calcium channel in human HEK293 cells by whole-cell patch-clamp method	[PMID: 23395659]
LLC-PK1	IC₅₀	10 3 Compound: Mibefradil	Inhibition of P-glycoprotein, mouse L-mdr1b expressed in LLC-PK1 epithelial cells using calcein-AM polarisation assay Inhibition of P-glycoprotein, mouse L-mdr1b expressed in LLC-PK1 epithelial cells using calcein-AM polarisation assay	[PMID: 12699389]
MDA-MB-231	IC₅₀	>100 3 Compound: 8	Inhibition of Orai1-mediated store operated Ca2+ entry in human MDA-MB-231 cells assessed as reduction in BAPTA-induced Ca2+ depletion-stimulated SOCE activity preincubated for 15 mins followed by BAPTA addition in presence of extracellular Ca2+ by PBX-ba Inhibition of Orai1-mediated store operated Ca2+ entry in human MDA-MB-231 cells assessed as reduction in BAPTA-induced Ca2+ depletion-stimulated SOCE activity preincubated for 15 mins followed by BAPTA addition in presence of extracellular Ca2+ by PBX-ba	[PMID: 27856238]
HEK293	IC₅₀	0.84 3 Compound: Midefradil	Concentration of the compounds required for inhibition of HEK293 cells (alpha1G T-type) Concentration of the compounds required for inhibition of HEK293 cells (alpha1G T-type)	[PMID: 15177437]
Oocyte	IC₅₀	108 3 Compound: Mibefradil	Inhibition of L-type calcium channel measured using 2-electrode voltage-clamp in Xenopus oocyte heterologically expressing alpha-1C subunit Inhibition of L-type calcium channel measured using 2-electrode voltage-clamp in Xenopus oocyte heterologically expressing alpha-1C subunit	[PMID: 22761000]
HEK293	IC₅₀	0.84 3 Compound: mibefradil	Inhibition of alpha-1G T-type calcium channel expressed in HEK293 cells by electrophysiological method Inhibition of alpha-1G T-type calcium channel expressed in HEK293 cells by electrophysiological method	[PMID: 17074493]
Oocyte	IC₅₀	288 3 Compound: Mibefradil	Inhibition of L-type calcium channel measured using 2-electrode voltage-clamp in Xenopus oocyte heterologically expressing alpha-1C subunit Inhibition of L-type calcium channel measured using 2-electrode voltage-clamp in Xenopus oocyte heterologically expressing alpha-1C subunit	[PMID: 22761000]
MDA-MB-231	IC₅₀	52.1 3 Compound: 8	Inhibition of Orai1-mediated store operated Ca2+ entry in human MDA-MB-231 cells assessed as reduction of SERCA inhibition-induced ER release preincubated for 15 mins followed by CPA addition by PBX-based FLIPR assay Inhibition of Orai1-mediated store operated Ca2+ entry in human MDA-MB-231 cells assessed as reduction of SERCA inhibition-induced ER release preincubated for 15 mins followed by CPA addition by PBX-based FLIPR assay	[PMID: 27856238]
HEK293	IC₅₀	0.86 3 Compound: Mibefradil	Inhibition of T-type CaV3.1 channel expressed in HEK293 cells assessed as inhibition of calcium current by manual patch-clamp assay Inhibition of T-type CaV3.1 channel expressed in HEK293 cells assessed as inhibition of calcium current by manual patch-clamp assay	[PMID: 20621730]
MIA PaCa-2	IC₅₀	18.4 3 Compound: Mibefradil	Cytotoxicity against human MIAPaCa2 cells after 48 hrs by MTT assay Cytotoxicity against human MIAPaCa2 cells after 48 hrs by MTT assay	[PMID: 24529871]
SK-OV-3	IC₅₀	20.54 3 Compound: Mibefradil	Cytotoxicity against human SKOV3 cells after 48 hrs by MTT assay Cytotoxicity against human SKOV3 cells after 48 hrs by MTT assay	[PMID: 24220170]
HEK293	IC₅₀	1 3 Compound: Mibefradil	Inhibition of human T-type calcium channel Cav3.2 expressed in T-Rex293 cells by whole cell patch clamp assay Inhibition of human T-type calcium channel Cav3.2 expressed in T-Rex293 cells by whole cell patch clamp assay	[PMID: 23200256]
HEK293	IC₅₀	181 1 Compound: I, Posicor	Inhibition of recombinant Cav3.2 channel (unknown origin) expressed in HEK293 cells assessed as effect on calcium flux incubated for 3 mins by FLIPR assay Inhibition of recombinant Cav3.2 channel (unknown origin) expressed in HEK293 cells assessed as effect on calcium flux incubated for 3 mins by FLIPR assay	[PMID: 26231163]
HEK293	IC₅₀	202 1 Compound: I, Posicor	Inhibition of recombinant Cav1.2 channel (unknown origin) expressed in HEK293 cells assessed as effect on calcium flux incubated for 3 mins by FLIPR assay Inhibition of recombinant Cav1.2 channel (unknown origin) expressed in HEK293 cells assessed as effect on calcium flux incubated for 3 mins by FLIPR assay	[PMID: 26231163]
HEK293	IC₅₀	1.3 3 Compound: I, Posicor	Inhibition of human ERG expressed in HEK cells by patch clamp assay Inhibition of human ERG expressed in HEK cells by patch clamp assay	[PMID: 26231163]
HEK293	IC₅₀	1.34 3 Compound: Mibefradil	Inhibition of T-type [Ca2+] channel (alpha1G) expressed in HEK293 cells Inhibition of T-type [Ca2+] channel (alpha1G) expressed in HEK293 cells	[PMID: 15603940]
Oocyte	IC₅₀	108 3 Compound: Mibefradil	Inhibition of L-type calcium channel measured using 2-electrode voltage-clamp in Xenopus oocyte heterologically expressing alpha-1C subunit Inhibition of L-type calcium channel measured using 2-electrode voltage-clamp in Xenopus oocyte heterologically expressing alpha-1C subunit	[PMID: 22761000]
HEK293	IC₅₀	1.34 3 Compound: Mibefradil	Ability to block calcium channel T type 3.1v expressed in HEK293 cells by whole cell patch clamp method Ability to block calcium channel T type 3.1v expressed in HEK293 cells by whole cell patch clamp method	[PMID: 16876404]
Oocyte	IC₅₀	288 3 Compound: Mibefradil	Inhibition of L-type calcium channel measured using 2-electrode voltage-clamp in Xenopus oocyte heterologically expressing alpha-1C subunit Inhibition of L-type calcium channel measured using 2-electrode voltage-clamp in Xenopus oocyte heterologically expressing alpha-1C subunit	[PMID: 22761000]
HEK293	IC₅₀	1.34 3 Compound: Mibefradil	Inhibition of T type calcium channel subunit alpha-1G expressed in HEK293 cells assessed as effect on T-type calcium currents by patch clamp method Inhibition of T type calcium channel subunit alpha-1G expressed in HEK293 cells assessed as effect on T-type calcium currents by patch clamp method	[PMID: 17150365]
HEK293	IC₅₀	1.34 3 Compound: Mibefradil	Inhibition of T-type calcium channel alpha1G expressed in human HEK293 cells assessed as inhibition of peak currents by whole-cell patch-clamp method Inhibition of T-type calcium channel alpha1G expressed in human HEK293 cells assessed as inhibition of peak currents by whole-cell patch-clamp method	[PMID: 20382529]
SK-OV-3	IC₅₀	20.54 3 Compound: Mibefradil	Cytotoxicity against human SKOV3 cells after 48 hrs by MTT assay Cytotoxicity against human SKOV3 cells after 48 hrs by MTT assay	[PMID: 24220170]
HEK293	IC₅₀	1.34 3 Compound: Mibefradil	Inhibition of T-type alpha1G channel expressed in HEK293 cells by whole-cell patch-clamp method Inhibition of T-type alpha1G channel expressed in HEK293 cells by whole-cell patch-clamp method	[PMID: 20659804]
HEK293	IC₅₀	1.34 3 Compound: Mibefradil	Inhibition of T-type alpha1G calcium channel expressed in HEK293 cells assessed as Kcl-induced depolarization Inhibition of T-type alpha1G calcium channel expressed in HEK293 cells assessed as Kcl-induced depolarization	[PMID: 21126876]
HEK293	IC₅₀	1.34 3 Compound: mibefradil	Inhibition of T-type calcium channel Cav3.1 expressed in HEK293 cells co-expressing alpha1G subunit by whole-cell patch clamp method Inhibition of T-type calcium channel Cav3.1 expressed in HEK293 cells co-expressing alpha1G subunit by whole-cell patch clamp method	[PMID: 17064894]
HEK293	IC₅₀	1.34 3 Compound: mibefradil	Inhibition of T-type calcium channel Cav3.1 expressed in HEK293 cells co-expressing alpha1G subunit and Kir2.1 potassium channel by patch-clamp assay Inhibition of T-type calcium channel Cav3.1 expressed in HEK293 cells co-expressing alpha1G subunit and Kir2.1 potassium channel by patch-clamp assay	[PMID: 17092715]
HEK293	IC₅₀	1.34 3 Compound: mibefradil	Inhibition of T-type calcium channel Cav3.1 alpha-1G subunit expressed in HEK293 cells assessed as calcium current by patch-clamp assay Inhibition of T-type calcium channel Cav3.1 alpha-1G subunit expressed in HEK293 cells assessed as calcium current by patch-clamp assay	[PMID: 17869104]
HEK293	IC₅₀	1.34 3 Compound: mibefradil	Antagonist activity at T type calcium channel alpha1G expressed in HEK293 cells assessed as inhibition of peak currents by whole-cell patch-clamp method Antagonist activity at T type calcium channel alpha1G expressed in HEK293 cells assessed as inhibition of peak currents by whole-cell patch-clamp method	[PMID: 18625556]
HEK293	IC₅₀	181 1 Compound: I, Posicor	Inhibition of recombinant Cav3.2 channel (unknown origin) expressed in HEK293 cells assessed as effect on calcium flux incubated for 3 mins by FLIPR assay Inhibition of recombinant Cav3.2 channel (unknown origin) expressed in HEK293 cells assessed as effect on calcium flux incubated for 3 mins by FLIPR assay	[PMID: 26231163]
HEK293	IC₅₀	202 1 Compound: I, Posicor	Inhibition of recombinant Cav1.2 channel (unknown origin) expressed in HEK293 cells assessed as effect on calcium flux incubated for 3 mins by FLIPR assay Inhibition of recombinant Cav1.2 channel (unknown origin) expressed in HEK293 cells assessed as effect on calcium flux incubated for 3 mins by FLIPR assay	[PMID: 26231163]
HeLa	IC₅₀	4.32 3 Compound: Mibefradil	Inhibition of Ebolavirus glycoprotein/matrix protein VP40 entry in human HeLa cells after 4.5 hrs beta-lactamase reporter assay Inhibition of Ebolavirus glycoprotein/matrix protein VP40 entry in human HeLa cells after 4.5 hrs beta-lactamase reporter assay	[PMID: 29624387]
Hepatocyte	IC₅₀	0.873 1 Compound: Mibefradil	Antimicrobial activity against Plasmodium yoelii 265 liver infected in mammalian hepatocytes after 48 hrs Antimicrobial activity against Plasmodium yoelii 265 liver infected in mammalian hepatocytes after 48 hrs	[PMID: 18212104]
LLC-PK1	IC₅₀	1.8 3 Compound: Mibefradil	Inhibition of P-glycoprotein, human L-MDR1 expressed in LLC-PK1 epithelial cells using calcein-AM polarisation assay Inhibition of P-glycoprotein, human L-MDR1 expressed in LLC-PK1 epithelial cells using calcein-AM polarisation assay	[PMID: 12699389]
LLC-PK1	IC₅₀	1.8 3 Compound: Mibefradil	TP_TRANSPORTER: inhibition of Calcein-AM efflux in MDR1-expressing LLC-PK1 cells TP_TRANSPORTER: inhibition of Calcein-AM efflux in MDR1-expressing LLC-PK1 cells	[PMID: 12699389]
LLC-PK1	IC₅₀	10 3 Compound: Mibefradil	Inhibition of P-glycoprotein, mouse L-mdr1b expressed in LLC-PK1 epithelial cells using calcein-AM polarisation assay Inhibition of P-glycoprotein, mouse L-mdr1b expressed in LLC-PK1 epithelial cells using calcein-AM polarisation assay	[PMID: 12699389]
LLC-PK1	IC₅₀	10 3 Compound: Mibefradil	TP_TRANSPORTER: inhibition of Calcein-AM efflux in Mdr1b-expressing LLC-PK1 cells TP_TRANSPORTER: inhibition of Calcein-AM efflux in Mdr1b-expressing LLC-PK1 cells	[PMID: 12699389]
LLC-PK1	IC₅₀	7.4 3 Compound: Mibefradil	Inhibition of P-glycoprotein, mouse L-mdr1a expressed in LLC-PK1 epithelial cells using calcein-AM polarisation assay Inhibition of P-glycoprotein, mouse L-mdr1a expressed in LLC-PK1 epithelial cells using calcein-AM polarisation assay	[PMID: 12699389]
LLC-PK1	IC₅₀	7.4 3 Compound: Mibefradil	TP_TRANSPORTER: inhibition of Calcein-AM efflux in Mdr1a-expressing LLC-PK1 cells TP_TRANSPORTER: inhibition of Calcein-AM efflux in Mdr1a-expressing LLC-PK1 cells	[PMID: 12699389]
MDA-MB-231	IC₅₀	52.1 3 Compound: 8	Inhibition of Orai1-mediated store operated Ca2+ entry in human MDA-MB-231 cells assessed as reduction of SERCA inhibition-induced ER release preincubated for 15 mins followed by CPA addition by PBX-based FLIPR assay Inhibition of Orai1-mediated store operated Ca2+ entry in human MDA-MB-231 cells assessed as reduction of SERCA inhibition-induced ER release preincubated for 15 mins followed by CPA addition by PBX-based FLIPR assay	[PMID: 27856238]
MDA-MB-231	IC₅₀	> 100 3 Compound: 8	Inhibition of Orai1-mediated store operated Ca2+ entry in human MDA-MB-231 cells assessed as reduction in BAPTA-induced Ca2+ depletion-stimulated SOCE activity preincubated for 15 mins followed by BAPTA addition in presence of extracellular Ca2+ by PBX-ba Inhibition of Orai1-mediated store operated Ca2+ entry in human MDA-MB-231 cells assessed as reduction in BAPTA-induced Ca2+ depletion-stimulated SOCE activity preincubated for 15 mins followed by BAPTA addition in presence of extracellular Ca2+ by PBX-ba	[PMID: 27856238]
MIA PaCa-2	IC₅₀	18.4 3 Compound: Mibefradil	Cytotoxicity against human MIAPaCa2 cells after 48 hrs by MTT assay Cytotoxicity against human MIAPaCa2 cells after 48 hrs by MTT assay	[PMID: 24529871]
Oocyte	IC₅₀	108 3 Compound: Mibefradil	Inhibition of L-type calcium channel measured using 2-electrode voltage-clamp in Xenopus oocyte heterologically expressing alpha-1C subunit Inhibition of L-type calcium channel measured using 2-electrode voltage-clamp in Xenopus oocyte heterologically expressing alpha-1C subunit	[PMID: 22761000]
Oocyte	IC₅₀	288 3 Compound: Mibefradil	Inhibition of L-type calcium channel measured using 2-electrode voltage-clamp in Xenopus oocyte heterologically expressing alpha-1C subunit Inhibition of L-type calcium channel measured using 2-electrode voltage-clamp in Xenopus oocyte heterologically expressing alpha-1C subunit	[PMID: 22761000]
SK-OV-3	IC₅₀	20.54 3 Compound: Mibefradil	Cytotoxicity against human SKOV3 cells after 48 hrs by MTT assay Cytotoxicity against human SKOV3 cells after 48 hrs by MTT assay	[PMID: 24220170]

体外実験

Mibefradil inhibits reversibly the T- and L-type currents with IC₅₀ values of 2.7 and 18.6 μM, respectively. The inhibition of the L-type current is voltage-dependent, whereas that of the T-type current is not. Ro 40-5967 blocks T-type current already at a holding potential of -100 mV^[1] At a higher concentration (20 μM), Mibefradil reduces the amplitude of excitatory junction potentials (by 37±10 %), slows the rate of repolarisation (by 44±16 %) and causes a significant membrane potential depolarisation (from 83±1 mV to 71±5 mV). At a higher Mibefradil concentration (20 μM) there is significant membrane potential depolarisation and a slowing of repolarisation. These actions of Mibefradil are consistent with K⁺ channel inhibition, which has been shown to occur in human myoblasts and other cells^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

体内実験

The hearing thresholds of the 24-26 week old C57BL/6J mice differed following the 4-week treatment period. The hearing threshold at 24 kHz is significantly decreased in the Mibefradil-treated and benidipine-treated groups compared with the saline-treated group (P<0.05)^[3]. Compared with the saline-treated group, rats receiving Mibefradil or Ethosuximide show significant lower Ca_V3.2 expression in the spinal cord and DRG^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

臨床実験

分子量

495.63

分子式

C₂₉H₃₈FN₃O₃

CAS 番号

116644-53-2

Appearance

Solid

Color

White to off-white

SMILES

O=C(O[C@@]1(CCN(CCCC2=NC3=CC=CC=C3N2)C)[C@@H](C(C)C)C4=C(C=C(F)C=C4)CC1)COC

輸送条件

Room temperature in continental US; may vary elsewhere.

保管条件

-20°C, sealed storage, away from moisture and light

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

純度とドキュメンテーション

取扱説明書 (2659 KB)

参考文献

[1]. Mehrke G, et al. The Ca(++)-channel blocker Ro 40-5967 blocks differently T-type and L-type Ca++ channels. J Pharmacol Exp Ther. 1994 Dec;271(3):1483-8. [Content Brief]

[2]. Brain KL, et al. The sources and sequestration of Ca(2+) contributing to neuroeffector Ca(2+) transients in the mouse vas deferens. J Physiol. 2003 Dec 1;553(Pt 2):627-35. [Content Brief]

[3]. Yu YF, et al. Protection of the cochlear hair cells in adult C57BL/6J mice by T-type calcium channel blockers. Exp Ther Med. 2016 Mar;11(3):1039-1044. [Content Brief]

[4]. Shiue SJ, et al. Chronic intrathecal infusion of T-type calcium channel blockers attenuates CaV3.2 upregulation in nerve-ligated rats. Acta Anaesthesiol Taiwan. 2016 Oct 17. pii: S1875-4597(16)30071-6. [Content Brief]

動物実験
^[3]^[4]

Mice^[3]
A total of 30 male C57BL/6J mice (age, 6-8 weeks) are randomized into three groups for the detection of three calcium channel receptor subunits α1G, α1H and α1I, using reverse transcription-quantitative polymerase chain reaction (RT-qPCR). In addition, a further 30 C57BL/6J male mice (age, 24-26 weeks) are allocated at random into three treatment groups: Saline, Mibefradil and benidipine. Each group is subjected to auditory brainstem recording (ABR) and distortion product otoacoustic emission (DPOAE) tests following treatment. Mibefradil and benidipine are dissolved in physiological saline solution. A preliminary experiment led to the selection of dosages of 30 mg/kg/day Mibefradil and 10 mg/kg/day Benidipine. The drugs are administered to the mice by gavage for four consecutive weeks.
Rats^[4]
Male Sprague-Dawley rats (200-250 g) are used for right L5/6 SNL to induce neuropathic pain. Intrathecal infusion of saline or TCC blockers [Mibefradil (0.7 μg/h) or Ethosuximide (60 μg/h)] is started after surgery for 7 days. Fluorescent immunohistochemistry and Western blotting are used to determine the expression pattern and protein level of Ca_V3.2. Hematoxylin-eosin and toluidine blue staining are used to evaluate the neurotoxicity of tested agents.

MedChemExpress (MCE) はこれらの方法の精度を確認していません。こちらは参照専用です。

参考文献

[1]. Mehrke G, et al. The Ca(++)-channel blocker Ro 40-5967 blocks differently T-type and L-type Ca++ channels. J Pharmacol Exp Ther. 1994 Dec;271(3):1483-8. [Content Brief]

[2]. Brain KL, et al. The sources and sequestration of Ca(2+) contributing to neuroeffector Ca(2+) transients in the mouse vas deferens. J Physiol. 2003 Dec 1;553(Pt 2):627-35. [Content Brief]

[3]. Yu YF, et al. Protection of the cochlear hair cells in adult C57BL/6J mice by T-type calcium channel blockers. Exp Ther Med. 2016 Mar;11(3):1039-1044. [Content Brief]

[4]. Shiue SJ, et al. Chronic intrathecal infusion of T-type calcium channel blockers attenuates CaV3.2 upregulation in nerve-ligated rats. Acta Anaesthesiol Taiwan. 2016 Oct 17. pii: S1875-4597(16)30071-6. [Content Brief]

Mibefradil Related Classifications

Molarity Calculator
Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

質量		濃度		体積		分子量 *
	=		×		×

The dilution calculator equation

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

一般には略語で表示されます：C₁V₁ = C₂V₂

濃度 _（開始）	×	体積 _（開始）	=	濃度 _（終了）	×	体積 _（終了）
	×		=		×
C1		V1		C2		V2

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Mibefradil116644-53-2Ro 40-5967Calcium ChannelCa2+ channelsCa channelsInhibitorinhibitorinhibit

日本の代理先をお選びくださいナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
製品名			カスタマ需要量 *
お名前 *			タイトル
メールアドレス *			電話番号 *
デパートメント			組纖名 *
市区町村			都道府県
国或いは地域 *
必ず会社名を記載ください。個人への返信は行いません。
備考

製品名			Lot #
お名前 *			メールアドレス *
電話番号 *			部門 *
組纖名 *			国或いは地域 *
備考

Mibefradil (Synonyms: Ro 40-5967)

Other Forms of Mibefradil:

顧客検証

おすすめ

•関連スクリーニングライブラリ:

•関連小分子:

•関連タンパク質:

Calcium Channel アイソフォーム固有の製品をすべて表示:

生物活性

プロトコル

純度とドキュメンテーション

参考文献

カスタマーレビュー

Mibefradil Related Classifications

Molarity Calculator

Dilution Calculator

The molarity calculator equation

The dilution calculator equation

Keywords:

最近チェックした製品:

お名前
メール *

	Sorry, but the email address you supplied was invalid.

Mibefradil (Synonyms: Ro 40-5967)

Other Forms of Mibefradil:

Mibefradil 関連抗体

顧客検証

おすすめ

•関連スクリーニングライブラリ:

•関連小分子:

•関連タンパク質:

Calcium Channel アイソフォーム固有の製品をすべて表示:

生物活性

プロトコル

純度とドキュメンテーション

参考文献

カスタマーレビュー

Mibefradil 関連抗体

Mibefradil Related Classifications

Molarity Calculator

Dilution Calculator

The molarity calculator equation

The dilution calculator equation

Keywords:

最近チェックした製品:

カスタマーレビュー

Request for HNMR Report

Request for HNMR Report